[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sudden-cardiac-death-due-to-cardiac-arrhythmia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sudden-cardiac-death-due-to-cardiac-arrhythmia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,80,108,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100634886","odssey-scdidentification-of-markers-to-predict-the-risk-of-sudden-cardiac-death-in-moderated-lvef-in-ischemic-cardiomyopathy-100634886",false,"NCT07545512","ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY","ODISSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY (ODISSEY-SCD","ODISSEY","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Hospitalized for acute STEMI within 6 months (Type 1 myocardial infarction according to ESC recommendations, Thygesen EHJ 2018).\n* Left ventricular ejection fraction between 35% and 50% at least 40 days after acute myocardial infarction (see above).\n* Under optimal tolerated medical treatment.\n* Covered by a social security scheme.\n* Legally competent to give voluntary informed consent to participate in the study.\n* Patient who will not participate in further studies involving an investigational drug or device until the end of the trial (i.e. 60 months). Participation in registries is authorized\n\nExclusion Criteria:\n\n* Presence of a secondary prevention indication for implantation of an implantable automatic defibrillator (ICD)\n* Presence of a pacemaker\n* Administration of ventricular antiarrhythmic drugs other than beta-blockers (i.e. amiodarone, sotalol, flecainide)\n* Patients with systemic diseases (cancer, liver failure or end-stage renal disease)\n* Patients with assessed life expectancy \\\u003C 1 year.\n* Age \\> 80\n* Adult patient under legal protection (guardianship, curatorship or other legal protection measure)\n* The subject is pregnant or nursing or positive beta HCG for women of childbearing age\n* Patient participating in another clinical research protocol involving an investigational drug or device within the last 30 days (participation in a registry is permitted at the same time).","ALL","18 Years","80 Years",{"count":21,"type":22},400,"ESTIMATED","INTERVENTIONAL",[25],"NA","Although advances in treatment and patient management have considerably improved post-infarction prognosis, the risk of sudden cardiac death remains a major concern. Sudden cardiac death (SCD) is defined as an unexpected death occurring within one hour of the onset of symptoms, often of arrhythmic origin. In patients who have survived a myocardial infarction, sudden death represents a persistent threat. This risk is often associated with complications such as left ventricular dysfunction, malignant ventricular arrhythmias, and structural alterations of the myocardium, all of which can favor the development of fatal cardiac events. Among the risk factors identified, reduced left ventricular ejection fraction, a history of ventricular arrhythmias and the presence of extensive scarring of the myocardium are particularly significant.\n\nAssessing the risk of SCD in post-infarction patients is crucial to determining appropriate prevention strategies, such as implanting automatic implantable defibrillators (ICDs). Assessment tools are varied, but currently only left ventricular ejection fraction (LVEF) \\\u003C 35% is identified and validated. However, this risk stratification is unsatisfactory, particularly in view of SCD in patients with a history of myocardial infarction and a moderately impaired LVEF (between 35 and 50%). Although the initial treatment of myocardial infarction is essential for the patient's immediate survival, managing the risk of sudden death in the long term remains a major clinical challenge. A multiparametric approach is needed to optimize prognosis and prevent premature death in these patients.",[28,29],"Myocardial Infarction (MI)","Sudden Cardiac Death Due to Cardiac Arrhythmia",[31],"Sudden cardiac death in patients with ischemic heart disease and moderately impaired left ventricular ejection fraction (between 35 and 50%).","NOT_YET_RECRUITING","2026-06-12",{"date":35,"type":36},"2026-06-15","ACTUAL",{"date":38,"type":22},"2026-07-01",{"date":40,"type":22},"2033-07-01",{"name":42,"class":43},"University Hospital, Clermont-Ferrand","OTHER",10,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100626540","loop-recorder-implantation-in-patients-with-mitral-annular-disjunction-100626540","NCT07436962","Loop Recorder Implantation in Patients With Mitral Annular Disjunction","ILR MAD IIT","Inclusion Criteria:\n\n* age between 18 and 60 years\n* patient not incapacitated\n* mitral annular disjunction confirmed by echocardiography\n* MR scan confirmed late-type gadolinium enhancement in the myocardium\n\nExclusion Criteria:\n\n* lack of informed consent\n* age under 18 years\n* limited capability\n* guardianship\n* active infection\n* cancer\n* previous ICD implantation\n* indication for ICD or ILR implantation based on current recommendation","60 Years",{"count":54,"type":22},20,[25],"The goal of clinical trial is to prospectively collect data to investigate the prevalence of arrhythmia in young patients diagnosed with mitral annular disjunction who have no indication for implantable cardioverter defibrillator (ICD) or implantable loop recorder (ILR) implantation according to the current guideline. The study population is young (age 18-60), the participating patients have mitral annular disjunction confirmed by echocardiography and MR scan confirmed late-type gadolinium enhancement in the myocardium. This patient population has an increased risk of ventricular arrhythmias and sudden cardiac death. The investigators plan to implant 20 BioMonitor IIIm ILRs over a year in patients with mild or uncertain symptoms (dizziness, palpitations) and no malignant arrhythmias.\n\nAims of the study:\n\n1. Screening of asymptomatic patients with MAD for arrhythmia.\n2. In case of symptoms, to prove or exclude the underlying arrhythmia.\n\nBioMonitor IIIm ILR implantation is planned in the following patient population:\n\n1. Inclusion of 20 patients with mitral annular disjunction confirmed by echocardiography and late gadolinium enhancement in the myocardium by MRI.\n2. Only patients who do not meet the current indication for ICD or ILR implantation based on the current recommendation will be included in the study.",[58,59,60,29,61],"Mitral Annular Disjunction","Mitral Valve","Arrhythmia Ventricular","Loop Recorder",[63,64,65,66,67,68],"mitral annular disjunction","MAD","sudden cardiac death","loop recorder","ventricular arrhythmia","mitral valve","RECRUITING","2026-02-27",{"date":72,"type":36},"2026-03-02",{"date":74,"type":36},"2025-12-05",{"date":76,"type":22},"2030-02",{"name":78,"class":43},"Gottsegen National Cardiovascular Institute",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100584356","dna-methylation-in-brugada-syndrome-and-risk-of-sudden-cardiac-death-100584356","NCT06888271","DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death","DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death (ANDROMEDA)","ANDROMEDA","Inclusion Criteria:\n\n* Brugada syndrome was confirmed when the 12-lead ECG showed ST-segment elevation with a type-1 morphology of ≥2 mm in ≥1 right precordial lead either spontaneously or after a provocative drug test (intravenous administration of a Class I antiarrhythmic) in the absence of any structural heart disease.\n* \\>18 years\n* Unrelated patients\n\nExclusion Criteria:\n\n* Related patients\n* Not type 1 Br patter",true,{"count":44,"type":22},"OBSERVATIONAL","The goal of this observational study is to evaluate if there are differences in DNA methylation of peripheral blood in patients with Brugada syndrome and healthy subjects. The main question it aims to answer is:\n\nDoes DNA methylation changes distinguish Brugada patients from healthy controls?\n\nDoes DNA methylation changes distinguish Brugada patients with high versus low risk of sudden cardiac death?",[93,29],"Brugada Syndrome",[95,96,97,98],"DNA methylation","Liquid biopsy","Sudden cardiac death","Brugada syndrome","2025-03-20",{"date":101,"type":36},"2025-03-24",{"date":103,"type":22},"2025-05",{"date":105,"type":22},"2026-07",{"name":107,"class":43},"University of Campania Luigi Vanvitelli",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":117,"studyType":90,"phases":4,"briefSummary":118,"conditions":119,"keywords":124,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":79},"100577915","tampere-coronary-artery-disease-and-sudden-cardiac-arrest-study-100577915","NCT06804499","Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study","CADSCA","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. A patient who lives in the area of 'Wellbeing Services County of Pirkanmaa' and seeks treatment for coronary artery disease (CAD).\n3. CAD is diagnosed with invasive coronary angiogram or computed tomography angiogram (CTA) which is evaluated by cardiologists based on current guidelines for stenosis level evaluation and fractional flow reserve (FFR) results.\n4. An invasive coronary angiogram or CTA is done within three (3) months.\n5. Good or moderate everyday functional ability\n\nExclusion Criteria:\n\n1. Life expectancy \\\u003C1 months.\n2. A significant valvular heart disease treated previously (endovascular or surgical) or requires treatment (endovascular or surgical) in the next three (3) months.\n3. Previously implanted cardioverter-defibrillators (ICD) or will be implanted in the next three (3) months.\n4. An active malignancy (ongoing treatment for a solid tumour, metastatic solid tumour, fast progressing haematological malignancy, or equal malignant disease).\n5. A significant neurodegenerative disease (dementia, Mini-Mental State Examination (MMSE) \\\u003C23 or equivalenneurodegenerative disease affecting everyday functional ability, like ALS, myositis, prograded MS-disease or Parkinson's disease).\n6. Intellectual disability or a significant disability affecting cognitive functions\n7. Do-not-resuscitate (DNR) treatment decision\n\nSubgroup with blood samples:\n\nBlood samples are withdrawn from all study subjects under 76 years of age. Additionally, PaxGene samples are withdrawn from i) all study subjects under 65 years of age and ii) subjects between 65-76 years, if they have detected QRS-time\\>110ms in the latest ECG.",{"count":116,"type":22},4000,"15 Years","The goal of this observational study is to recognize clinical and genetic risk factors for sudden cardiac arrest (SCA) and death (SCD) in patients with coronary artery disease (CAD).\n\nThe main questions it aims to answer are:\n\nAre we able to recognize clinical or treatment-related risk factors for SCA or SCD? Can we identify new genetic risk factors for SCA or SCD in patients under 75 years?\n\nParticipants diagnosed with CAD answer a short survey about their medical history and socioeconomic status. A standard ECG addition to a five (5) minute ECG recording is taken from all the study subjects. In addition to a few short physiological tests (e.g. blood pressure, height, weight, grip strength), a blood sample is withdrawn from a selected group of study subjects.\n\nMedical healthcare records are used to follow all study subjects, and no follow-up visits are required.",[120,121,29,122,123],"Sudden Cardiac Arrest","Sudden Cardiac Death","Coronary Arterial Disease (CAD)","Acute Coronary Event",[65,125,126,127],"sudden cardiac arrest","coronary artery disease","acute coronary syndrome","2025-01-27",{"date":130,"type":36},"2025-02-03",{"date":132,"type":36},"2025-01-13",{"date":134,"type":22},"2042-12-31",{"name":136,"class":43},"Tampere Heart Hospital",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":144,"targetDuration":146,"studyType":90,"phases":4,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":79},"100572897","french-cohorte-extra-vascular-implantable-cardioverter-defibrillator-100572897","NCT06739239","French COhoRte Extra-Vascular Implantable CardiovErter DefibrillatoR","FOREVER","Inclusion Criteria:\n\n* All patients undergoing EV-ICD implantation\n\nExclusion Criteria:\n\n* Refusal of consent",{"count":145,"type":22},1000,"5 Years","Implantable cardioverter-defibrillators (ICDs) are widely recognized for their efficacy in reducing the risk of sudden cardiac death in high-risk patients. Nonetheless, there remains significant scope for improving outcomes through advancements in device technology and design. The extravascular cardioverter-defibrillator (EV-ICD) represents such an innovation, offering key advantages over other ICD systems. It incorporates a lead positioned in the substernal space, enabling the delivery of pause-prevention security pacing, antitachycardia pacing, and defibrillation energy similar to that provided by conventional transvenous ICDs.\n\nPrevious studies have demonstrated that EV-ICDs can be implanted safely and are capable of terminating majority of induced ventricular arrhythmias during implantation; however, follow-up data are limited to highly experienced selected centers and over a relatively small follow-up period (6-month follow-up). The FOREVER cohort study, initiated by the French Institute of Health and Medical Research, aims to evaluate the EV-ICD use in France.\n\nThis nationwide evaluation will provide an exhaustive collection of all EV-ICD implantations in France, offering valuable real-world evidence on the long-term safety and efficacy of the device.",[149,29],"Defibrillators, Implantable",[151,65,152],"Implantable cardioverter defibrillator","Extravascular Implantable Cardioverter-Defibrillator","2024-12-17",{"date":155,"type":36},"2024-12-20",{"date":157,"type":36},"2024-02-01",{"date":159,"type":22},"2030-12-31",{"name":161,"class":43},"Paris Sudden Death Expertise Center"]